Driving Change in Mental Health Through Science and Community

Beerse, Belgium (ots/PRNewswire) - Today, Janssen-Cilagare celebrating their 50 year commitment to researching anddeveloping innovative medicines to help improve the lives of peoplewith mental health problems. Back in 1958, the late Dr. Paul Janssendeveloped one of the first anti-psychotic drugs, which proved to be areal breakthrough in the treatment of schizophrenia and hailed theonset of a new era for patients being treated outside ofinstitutions. Over the past 50 years, Janssen-Cilag have developedseveral new compounds in the field of mental health, constantlyraising the bar in treatment expectations for many patients.

However, much more still needs to be done in the area of mentalhealth. Each patient is different and there is no drug or treatmentthat fits all, hence the need for continued cutting edge research anddevelopment to not only provide new medications but create tailormade treatment options for patients in the future.

Today, the company wishes to pay tribute to this heritage inpsychiatry, but also wants to look ahead and showcase its futuredevelopments in the treatment of diseases of the central nervoussystem. Now more than ever, Janssen-Cilag's aim and ultimate targetremains to fulfill unmet medical needs and to ensure the well-beingof patients and their families.

The celebration which takes place at Janssen Pharmaceutica inBeerse (Belgium) on Thursday, October 2nd, includes exhibitions andeducation for the company's employees and an academic session in theevening for psychiatrists and others interested in the field ofmental health.


Janssen-Cilag originates from the merger of the pharmaceuticalgroups within Johnson & Johnson (J&J), namely Janssen and Cilag. DrPaul Janssen established Janssen Pharmaceutica in 1953 in Belgium.Cilag (an acronym of Chemical Industry Laboratory AG) was founded inSwitzerland (Schaffhausen) in 1936.

More information about the company can be found athttp://www.janssen-cilag.com

ots Originaltext: Janssen-CilagIm Internet recherchierbar: http://www.presseportal.de

Contact:Sue Silk, Manager, CNS Communications EMEA, Tel: +44-1494-553955, E-mail: ssilk@its.jnj.com


Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Driving Change in Mental Health Through Science and Community